NiKang Therapeutics is a biotech company focused on developing small molecule oncology medicines. Its compound discovery is built on target structural biology and structure-based drug design. The company provides NKT2152, a small molecule HIF2α inhibitor for tumor growth inhibition or regression in multiple solid tumor xenograft models; NKT3447 that selectively suppresses the proliferation of cancer cells that depend on CDK2, while sparing normal cells; as well as small molecule compounds to inhibit KRAS G12D.